Results 21 to 30 of about 6,804 (189)
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia
Orphanet Journal of Rare Diseases, 2019 Background Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular dysplasia resulting in visceral arteriovenous malformations and smaller mucocutaneous telangiectasia.
C. L. Shovlin +19 more
doaj +1 more source
Genetic Variants and Clinical Phenotypes in Korean Patients With Hereditary Hemorrhagic Telangiectasia [PDF]
Clinical and Experimental Otorhinolaryngology, 2021 Objectives Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by recurrent epistaxis, telangiectasia, and visceral arteriovenous malformations (AVMs).
Bo-Gyeong Kim +17 more
doaj +1 more source
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
Orphanet Journal of Rare Diseases, 2019 Background Hereditary hemorrhagic telangiectasia (HHT) is a multisystemic inherited vascular dysplasia that leads to nosebleeds and visceral arteriovenous malformations (AVMs). Anti-angiogenic drugs thalidomide and bevacizumab have been increasingly used
Elisabetta Buscarini +10 more
doaj +1 more source
Общая реаниматология, 2021 The human electroencephalogram (EEG) constitutes a nonstationary, nonlinear electrophysiological signal resulting from synchronous firing of neurons in thalamocortical structures of the brain. Due to the complexity of the brain's physiological structures
G. Sobolova +4 more
doaj +1 more source
Orphanet Journal of Rare Diseases, 2019 Subjects with the rare autosomal dominant disease Hereditary Hemorrhagic Telangiectasia (HHT) may develop medical conditions that require antithrombotic therapy (AT).
Eleonora Gaetani +9 more
doaj +1 more source
Treatment of hereditary haemorrhagic telangiectasia with bevacizumab – what more needs to be known?
European Journal of Case Reports in Internal Medicine, 2023 Introduction: Hereditary haemorrhagic telangiectasia (HHT) is a rare multi-organ vascular disease. It is characterised by mucocutaneous telangiectasia, epistaxis, and arteriovenous malformations.
Edmond Morrissey +2 more
doaj +1 more source
Orphanet Journal of Rare Diseases, 2018 Hereditary haemorrhagic telangiectasia (HHT) is a multisystemic vascular dysplasia that leads to nosebleeds, anaemia due to blood loss, and arteriovenous malformations (AVMs) in organs such as the lungs, liver and brain. HHT is estimated to affect 85,000
Claire L. Shovlin +8 more
doaj +1 more source
Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report
Medicina, 2023 Herein, we present the first described hereditary hemorrhagic telangiectasia (HHT) patient treated with aflibercept for severe GI involvement after tachyphylaxis to bevacizumab, with promising results.
Bernat Villanueva +5 more
doaj +1 more source
Detection of relevant information in intrinsic mode functions
Visión Electrónica, 2020 The empirical mode decomposition (EMD) decomposes a local and adaptive time series into a finite set of intrinsic mode functions (IMF), AM-FM signals that allow to represent a non-linear and non-stationary model with the advantage of not losing the ...
Roberto Sebastián Hernández Santander +1 more
doaj +1 more source
Rare diseases in the elderly: a new perspective for the specialist in geriatrics
Geriatric Care, 2019 Rare diseases (RD) encompass a broad spectrum of highly heterogeneous illnesses characterized by a prevalence lower than 1:2000 in general population. Although relatively uncommon, when considered as a whole, these pathologies represent a relevant public
Carlo Sabbà +3 more
doaj +1 more source